Tacrolimus
FDA-approved product (capsule, oral), marketed as Astagraf Xl, Envarsus Xr, Prograf and 2 more.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 4 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Atopic eczema
- Delayed Graft Function
- Eczematoid dermatitis
- Immune system disease
- Kidney transplant
- Liver transplant
Indications ChEMBL records as approved, from FDA and DailyMed labels.
- WHO therapeutic group
- Agents for dermatitis, excluding corticosteroids; Calcineurin inhibitors
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA62.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli50.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae44.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- M. tuberculosis53.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Tacrolimus with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Mefloquine HydrochlorideExisting use: Malaria, Plasmodium falciparum malaria, Plasmodium vivax malaria81.8% AI-predicted activityagainst M. tuberculosisLab records exist8 registered studies
- KetoconazoleExisting use: Adrenal gland disease, Blastomycosis, Cushing syndrome and 3 more81.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- LevoketoconazoleExisting use: Adrenal gland disease, Adrenal gland hyperfunction, Cushing syndrome81.2% AI-predicted activityagainst M. tuberculosis6 registered studies
- Fluphenazine DecanoateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosis4 registered studies
- Fluphenazine EnanthateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- NifurtimoxExisting use: American trypanosomiasis, Chagas disease, Leishmaniasis and 1 more78.4% AI-predicted activityagainst M. tuberculosis19 registered studies
- Fluphenazine HydrochlorideExisting use: Mental or behavioural disorder, Psychosis77.8% AI-predicted activityagainst M. tuberculosis5 registered studies
- NitazoxanideExisting use: Amebiasis, Diarrhea77.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TopiramateExisting use: Epilepsy, Lennox-Gastaut syndrome, Migraine disorder and 1 more77.4% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TrabectedinExisting use: Cancer, Dedifferentiated liposarcoma, Leiomyosarcoma and 7 more76.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Chlorpromazine HydrochlorideExisting use: Conduct disorder, Mental or behavioural disorder, Nausea and vomiting and 3 more75.0% AI-predicted activityagainst M. tuberculosis33 registered studies
- ProchlorperazineExisting use: Anxiety disorder, Nausea and vomiting, Psychosis and 1 more74.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C
NCT00938860 · start 2009-09
Registered record
- Registry ID
- NCT00938860
- Conditions
- Hepatitis C; Liver Transplantation
- Interventions
- cyclosporin (Neoral); tacrolimus (Prograf)
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2009-09
- Completion
- 2013-05
- Enrolment
- 92
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHepatitis C; Liver TransplantationInterventioncyclosporin (Neoral); tacrolimus (Prograf)PhasePhase 4Registry statusCompletedLow Dose Thymoglobulin to Protect Kidney Function After Liver Transplant
NCT00970073 · start 2009-08
Registered record
- Registry ID
- NCT00970073
- Conditions
- Liver Transplantation
- Interventions
- Thymoglobulin 3mg total; Thymoglobulin 4.5mg total; Mycophenolate mofetil; tacrolimus 3-8; tacrolimus 8-12
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2009-08
- Completion
- 2015-12
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLiver TransplantationInterventionThymoglobulin 3mg total; Thymoglobulin 4.5mg total; Mycophenolate mofetil; tacrolimus 3-8 +1 morePhaseNot applicableRegistry statusCompletedMycophenolate Mofetil and Tacrolimus Versus Tacrolimus for the Treatment of Idiopathic Membranous Glomerulonephritis
NCT00843856 · start 2009-03-03
Registered record
- Registry ID
- NCT00843856
- Conditions
- Glomerulonephritis, Membranous
- Interventions
- tacrolimus; tacrolimus and mycophenolate mofetil
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2009-03-03
- Completion
- 2018-09-18
- Enrolment
- 40
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionGlomerulonephritis, MembranousInterventiontacrolimus; tacrolimus and mycophenolate mofetilPhasePhase 4Registry statusCompletedPolycystic Liver Disease in Kidney Transplant
NCT00934791 · start 2009-02
Registered record
- Registry ID
- NCT00934791
- Conditions
- Polycystic Liver Disease
- Interventions
- Tacrolimus; Sirolimus; Mycophenolate Mofetil; Prednisone
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Terminated
- Start
- 2009-02
- Completion
- 2012-12
- Enrolment
- 2
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPolycystic Liver DiseaseInterventionTacrolimus; Sirolimus; Mycophenolate Mofetil; PrednisonePhaseNot applicableRegistry statusTerminatedSteroid Withdrawal Immunosuppression After Renal Transplantation
NCT01550445 · start 2008-05
Registered record
- Registry ID
- NCT01550445
- Conditions
- Disorder Related to Renal Transplantation
- Interventions
- Prednisolone
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Unknown
- Start
- 2008-05
- Completion
- 2012-07
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDisorder Related to Renal TransplantationInterventionPrednisolonePhasePhase 4Registry statusUnknownA Randomized Study to Assess the Safety and Efficacy of Prograf vs Prograf-XL in de Novo Kidney Transplant Recipients
NCT00717678 · start 2007-12
Registered record
- Registry ID
- NCT00717678
- Conditions
- Kidney Transplantation; Transplantation Immunology; Host vs Graft Reaction
- Interventions
- Prograf-XL; Prograf; MMF
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2007-12
- Completion
- 2010-04
- Enrolment
- 73
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionKidney Transplantation; Transplantation Immunology; Host vs Graft ReactionInterventionPrograf-XL; Prograf; MMFPhasePhase 3Registry statusCompletedA Study of CellCept (Mycophenolate Mofetil) in Combination Therapy in Liver Transplant Patients.
NCT00545402 · start 2007-11
Registered record
- Registry ID
- NCT00545402
- Conditions
- Liver Transplantation
- Interventions
- Mycophenolate mofetil, adjusted dose; Tacrolimus; Corticosteroids, IV; Mycophenolate mofetil, Standard dose; Corticosteroids, PO
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2007-11
- Completion
- 2011-07
- Enrolment
- 180
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLiver TransplantationInterventionMycophenolate mofetil, adjusted dose; Tacrolimus; Corticosteroids, IV; Mycophenolate mofetil, Standard dose +1 morePhasePhase 4Registry statusCompletedOral Paricalcitol in Kidney Transplant Recipients
NCT00587158 · start 2007-01
Registered record
- Registry ID
- NCT00587158
- Conditions
- Transplant; Failure, Kidney; Renal Disease, End Stage; Hyperparathyroidism, Secondary
- Interventions
- Paricalcitol; Corticosteroid Avoidance Immune Suppression Protocol
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2007-01
- Completion
- 2011-11
- Enrolment
- 100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTransplant; Failure, Kidney; Renal Disease, End Stage; Hyperparathyroidism, SecondaryInterventionParicalcitol; Corticosteroid Avoidance Immune Suppression ProtocolPhaseNot applicableRegistry statusCompletedEfficacy and Safety of AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months), in Renal Transplant Patients
NCT00403416 · start 2006-10
Registered record
- Registry ID
- NCT00403416
- Conditions
- Kidney Transplantation
- Interventions
- AEB071; Mycophenolic Acid
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Completed
- Start
- 2006-10
- Completion
- 2008-05
- Enrolment
- 215
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionKidney TransplantationInterventionAEB071; Mycophenolic AcidPhasePhase 1 / Phase 2Registry statusCompletedTacrolimus and Mycophenolate Mofetil (MMF) in GVHD Prophylactic Regimen Compared to Tacrolimus and Methotrexate (MTX
NCT00360685 · start 2005-09
Registered record
- Registry ID
- NCT00360685
- Conditions
- Mucositis; Graft-versus-host Disease
- Interventions
- Tac+MTX; TAC + MMF
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2005-09
- Completion
- 2011-01
- Enrolment
- 89
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMucositis; Graft-versus-host DiseaseInterventionTac+MTX; TAC + MMFPhaseNot applicableRegistry statusCompletedStudy of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus
NCT00133367 · start 2005-08
Registered record
- Registry ID
- NCT00133367
- Conditions
- Multiple Myeloma; Non-Hodgkin's Lymphoma; Hodgkin's Disease; Myelogenous Leukemia; Lymphoblastic Leukemia
- Interventions
- Tacrolimus; Sirolimus; G-CSF; Antithymocyte globulin; Thymoglobulin; Fludarabine; Melphalan
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2005-08
- Completion
- 2011-11
- Enrolment
- 32
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMultiple Myeloma; Non-Hodgkin's Lymphoma; Hodgkin's Disease; Myelogenous Leukemia +1 moreInterventionTacrolimus; Sirolimus; G-CSF; Antithymocyte globulin +3 morePhasePhase 2Registry statusCompletedRapamycin for Immunosuppression and B Cell Modulation Post Stem Cell Transplant for Acute Lymphoblastic Leukemia (ALL)
NCT00795886 · start 2005-08
Registered record
- Registry ID
- NCT00795886
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- RAPAMYCIN
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2005-08
- Completion
- 2010-03
- Enrolment
- 63
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute Lymphoblastic LeukemiaInterventionRAPAMYCINPhasePhase 2Registry statusCompletedEffect of Rapid Steroid Withdrawal on Subclinical Markers of Rejection
NCT00133172 · start 2005-07
Registered record
- Registry ID
- NCT00133172
- Conditions
- Kidney Transplantation
- Interventions
- Tacrolimus; mycophenolate mofetil; Prednisone
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Terminated
- Start
- 2005-07
- Completion
- 2007-03
- Enrolment
- 85
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionKidney TransplantationInterventionTacrolimus; mycophenolate mofetil; PrednisonePhasePhase 4Registry statusTerminatedTacrolimus Ointment in Oral Lichen Planus
NCT01544842 · start 2004-08
Registered record
- Registry ID
- NCT01544842
- Conditions
- Oral Lichen Planus
- Interventions
- 0.1 % tacrolimus ointment; 0.1 % triamcinolone paste; Orabase paste
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Terminated
- Start
- 2004-08
- Completion
- 2015-07
- Enrolment
- 28
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOral Lichen PlanusIntervention0.1 % tacrolimus ointment; 0.1 % triamcinolone paste; Orabase pastePhaseNot applicableRegistry statusTerminatedIslet Allotransplantation With Steroid Free Immunosuppression
NCT00446264 · start 2003-05
Registered record
- Registry ID
- NCT00446264
- Conditions
- Type 1 Diabetes; Hypoglycemia; Metabolic Diseases
- Interventions
- islet transplantation; daclizumab - sirolimus - tacrolimus
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2003-05
- Completion
- 2009-02
- Enrolment
- 14
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionType 1 Diabetes; Hypoglycemia; Metabolic DiseasesInterventionislet transplantation; daclizumab - sirolimus - tacrolimusPhasePhase 2Registry statusCompleted